Associate Director
Frontage Laboratories, Inc
Lili Liao is an Associate Director for cell-based core lab at Frontage Labs. In this role, she leads the development, validation, and sample analysis of bioanalytical methods, including ADA (anti-drug antibodies), NAb (neutralizing antibodies), and biomarker assays. She has been establishing various platforms for neutralizing antibody assays at Frontage, such as competitive ligand binding assay, enzymatic based NAb assay, gene reporter assay, virus reporter assay, FAMA assay, in-cell western assay, and cell killing assay.
Additionally, she is a critical member of Frontage’s BGC program (Biologics, Gene, and Cell Therapy). Her expertise includes critical quality attributes assessment of mRNA therapeutics, TCID50 assay and cell-potency assays for virus-based gene therapy pipelines.